Status: Recruiting
Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors
This study is to assess the MTD and PK of NM6603 in adult patients with advanced solid tumors.
Participants needed: 30
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: NucMito Pharmaceuticals Co. Ltd.Updated: Jan 14, 2026Locations: 3
Eligibility criteria
Advanced solid tumors (primarily advanced colorectal cancer or triple-negative b... [+15]
Known hypersensitivity to NM6603 or its components [+25]